Premium
Correlations of CTLA‐4 exon‐1 49 A/G and promoter region 318C/T polymorphisms with the therapeutic efficacy of 131 I radionuclide in graves’ disease in Chinese Han population
Author(s) -
Han XinRui,
Wen Xin,
Wang Shan,
Fan ShaoHua,
Zhuang Juan,
Wang YongJian,
Zhang ZiFeng,
Li MengQiu,
Hu Bin,
Shan Qun,
Sun ChunHui,
Bao YaXing,
Wu DongMei,
Lu Jun,
Zheng YuanLin
Publication year - 2018
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.26327
Subject(s) - medicine , graves' disease , gastroenterology , exon , logistic regression , thyroid , haplotype , endocrinology , allele , gene , biology , genetics
Graves' disease is an autoimmune process in which the thyroid gland is triggered by autoantibodies, resulting in hyperthyroidism. The purpose of the present study is to elucidate whether exon‐1 49 A/G and promoter region 318C/T polymorphisms in the CTLA‐4 gene. This study consisted of 653 eligible patients with Graves' disease. After receiving 131I radionuclide therapy, these patients were classified into the remission and non‐remission groups. A logistic regression‐based model was used to analyze independent factors affecting the patient response to 131I radionuclide therapy. The results showed that CTLA‐4 49 A/G was closely related to the efficacy of 131 I treatment for Graves’ disease (AG + GG vs. AA: OR = 6.543, 95%CI = 2.611 ∼ 16.40, P < 0.001; G vs. A: OR = 3.482, 95%CI = 2.457 ∼ 4.934, P < 0.001). Moreover, the findings revealed that haplotype A‐C ( P < 0.001, OR = 3.592, 95%CI: 2.451 ∼ 5.262) and G‐C ( P < 0.001, OR = 0.282, 95%CI: 0.204 ∼ 0.391) were associated with the efficacy of 131 I therapy in treating Graves’ disease. Logistic regression analysis indicated that thyroid weight (OR = 0.963, 95%CI = 0.944 ∼ 0.982, P < 0.001) and CTLA‐4 exon‐1 49 A/G polymorphism (OR = 0.334, 95%CI = 0.233 ∼ 0.478, P < 0.001) independently affect the efficacy of 131 I therapy in Graves’ disease. These data indicated that CTLA‐4 exon‐1 49 A/G polymorphism may be associated with patient response to radionuclide 131 I therapy in Graves’ disease.